Consensus BioNTech SE Xetra

Equities

22UA

US09075V1026

Market Closed - Xetra Other stock markets 11:35:35 2024-05-17 EDT			After market 15:59:16
84.6 ^EUR	-1.46%		83.3	-1.54%

07:55pm	Sector Update: Health Care Stocks Softer Friday Afternoon	MT
07:42pm	Sector Update: Health Care	MT

Evolution of the average Target Price on BioNTech SE

Price target over the last 5 years

History of analyst recommendation changes

cd4c9e6d9b1b9f68f4236b23.90n3USH3KMqGs8mY_p8cLuFnOT0UZb7TkLwa1CHvNHI.pgqyIBPAaZXH0qfVz69PSKxSU01lAf-2xOU35GOoRSHaBYQDdrNxg7_Evg~64f1b6916c1f8083b02f2c7356e2a859

Analyst Recommendations on BioNTech SE

Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	10:41am	MT
Evercore ISI Starts BioNTech With In Line Rating, $100 Price Target	05-14	MT
BIONTECH : UBS remains Neutral	05-10	ZD
HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating	05-08	MT
BIONTECH : Deutsche Bank reaffirms its Neutral rating	05-08	ZD
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating	05-07	MT
BMO Capital Adjusts BioNTech Price Target to $122 From $123, Maintains Outperform Rating	05-07	MT
BIONTECH : Goldman Sachs reiterates its Neutral rating	05-07	ZD
BIONTECH : Jefferies gives a Neutral rating	05-06	ZD
BIONTECH : Gets a Neutral rating from Deutsche Bank	04-23	ZD
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating	03-27	MT
BIONTECH : Deutsche Bank remains Neutral	03-22	ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating	03-21	MT
BIONTECH : A miss is a miss	03-21
BIONTECH : Deutsche Bank reaffirms its Neutral rating	03-21	ZD
BIONTECH : Goldman Sachs reiterates its Neutral rating	03-21	ZD
BIONTECH : Jefferies sticks Neutral	03-20	ZD
BIONTECH : UBS gives a Neutral rating	03-20	ZD
BMO Capital Initiates Coverage on BioNTech With Outperform Rating, $127 Price Target	02-23	MT
Canaccord Genuity Adjusts Price Target on BioNTech to $171 From $168, Maintains Buy Rating	02-20	MT
HC Wainwright Adjusts BioNTech Price Target to $107 From $133, Maintains Buy Rating	01-23	MT
WHO sees 'incredibly low' COVID, flu vaccination rates as cases surge	01-12	RE
BIONTECH : UBS sticks Neutral	01-09	ZD
Oppenheimer Initiates BioNTech With Perform Rating	01-05	MT
BIONTECH : UBS gives a Neutral rating	12-14	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

85.54 EUR

Average target price

105.4 EUR

Spread / Average Target

+23.20%

High Price Target

158.7 EUR

Spread / Highest target

+85.53%

Low Price Target

82.88 EUR

Spread / Lowest Target

-3.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BioNTech SE

Evercore ISI
UBS	Eliana Merle
HC Wainwright
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
TD Cowen
BMO Capital
GOLDMAN SACHS	Chris Shibutani
JEFFERIES	Akash Tewari
alphavalue	Martin Schnee
Canaccord Genuity
Oppenheimer
Morgan Stanley
JPMorgan Chase
JPMORGAN	Jessica Fye
HSBC
Deutsche Bank Securities
BERENBERG	Zhiqiang Shu
Redburn
Berenberg Bank
BofA Securities
Jefferies & Co.
SVB Securities LLC
Kempen
DEUTSCHE BANK	Emmanuel Papadakis
SVB Leerink
BRYAN GARNIER	Olga Smolentseva
Bryan, Garnier & Co.
Wolfe Research
J.P. Morgan Chase

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar